TrialThe pharmacogenomics journal2020

Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer.

Harriet Johansson et al.PubMed ↗Publisher ↗

No numbers read from the abstract.